drugset / Trial / NCT06531369

Flumazenil Antagonism of Remimazolam in Kidney Transplant Patients

NCT06531369

Phase 1 Not yet recruiting 60 enrolled Qianfoshan Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

To investigate the effect of different doses of flumazenil antagonism on remimazolam plasma concentration in patients undergoing renal transplantation under general anesthesia.

Timeline

Start
2024-07
Primary completion
2025-12
Completion
2026-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Flumazenil Small molecule 0.3 mg
Comparator Flumazenil Small molecule 0.5 mg

Indications

No indication recorded.